TNYA · Insider Trading
Tenaya Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by TNYA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-11 | Whittemore Tingley | Chief Medical Officer | A | +49,000 | — |
| 2026-09-11 | Faraz Ali | Chief Executive Officer | A | +122,000 | — |
| 2026-08-17 | Whittemore Tingley | Chief Medical Officer | Sell | −7,424 | −$5.27K |
| 2026-08-17 | Faraz Ali | Chief Executive Officer | Sell | −22,232 | −$15.78K |
| 2026-07-14 | Eric J Hyllengren | Chief Financial Officer | A | +1,650,000 deriv. | — |
| 2026-05-29 | Deepak Srivastava | Director | A | +120,000 deriv. | — |
| 2026-05-29 | Catherine Stehman-Breen | Director | A | +120,000 deriv. | — |
| 2026-05-29 | Amy L. Burroughs | Director | A | +120,000 deriv. | — |
| 2026-05-29 | Karah Herdman Parschauer | Director | A | +120,000 deriv. | — |
| 2026-05-29 | June Lee | Director | A | +120,000 deriv. | — |
| 2026-05-29 | Jeffrey T. Walsh | Director | A | +120,000 deriv. | — |
| 2026-05-29 | R Sanders Williams | Director | A | +120,000 deriv. | — |
| 2026-05-19 | Tomohiro Higa | SVP, Finance | Sell | −1,485 | −$1.18K |
| 2026-05-19 | Whittemore Tingley | Chief Medical Officer | Sell | −3,121 | −$2.48K |
| 2026-05-19 | Faraz Ali | Chief Executive Officer | Sell | −3,390 | −$2.69K |
| 2026-02-26 | COLUMN GROUP III GP, LP | 10%+ Owner | Sell | −33,362,128 | −$19.04M |
| 2026-02-24 | Column Group Opportunity III GP, LP | 10%+ Owner | Sell | −6,637,872 | −$4.04M |
| 2026-02-17 | Tomohiro Higa | SVP, Finance | Sell | −3,469 | −$2.23K |
| 2026-02-17 | Faraz Ali | Chief Executive Officer | Sell | −14,862 | −$9.56K |
| 2026-02-17 | Whittemore Tingley | Chief Medical Officer | Sell | −5,160 | −$3.32K |
| 2026-02-12 | TCG Opportunity III GP, LLC | 10%+ Owner | Sell | −35,202,320 | −$24.34M |
| 2026-02-05 | Faraz Ali | Chief Executive Officer | A | +158,600 | — |
| 2026-02-05 | Whittemore Tingley | Chief Medical Officer | A | +48,750 | — |
| 2026-02-05 | Tomohiro Higa | SVP, Finance | A | +29,250 | — |
| 2025-11-17 | Faraz Ali | Chief Executive Officer | Sell | −3,126 | −$4.16K |
| 2025-11-17 | Whittemore Tingley | Chief Medical Officer | Sell | −2,877 | −$3.83K |
| 2025-11-17 | Tomohiro Higa | SVP, Finance | Sell | −1,367 | −$1.82K |
| 2025-08-18 | Whittemore Tingley | Chief Medical Officer | Sell | −5,053 | −$6.33K |
| 2025-08-18 | Tomohiro Higa | SVP, Finance | Sell | −2,962 | −$3.71K |
| 2025-08-18 | Faraz Ali | Chief Executive Officer | Sell | −14,533 | −$18.21K |
| 2025-05-30 | R Sanders Williams | Director | A | +107,400 deriv. | — |
| 2025-05-30 | Amy L. Burroughs | Director | A | +107,400 deriv. | — |
| 2025-05-30 | Deepak Srivastava | Director | A | +107,400 deriv. | — |
| 2025-05-30 | Catherine Stehman-Breen | Director | A | +107,400 deriv. | — |
| 2025-05-30 | David V Goeddel | Director | A | +107,400 deriv. | — |
| 2025-05-30 | Karah Herdman Parschauer | Director | A | +107,400 deriv. | — |
| 2025-05-30 | Jeffrey T. Walsh | Director | A | +107,400 deriv. | — |
| 2025-05-30 | June Lee | Director | A | +107,400 deriv. | — |
| 2025-05-16 | Faraz Ali | Chief Executive Officer | Sell | −3,189 | −$1.41K |
| 2025-05-16 | Tomohiro Higa | SVP, Finance | Sell | −1,390 | −$615 |
| 2025-05-16 | Whittemore Tingley | Chief Medical Officer | Sell | −2,937 | −$1.30K |
| 2025-03-10 | Tomohiro Higa | SVP, Finance | Sell | −2,482 | −$1.34K |
| 2025-03-10 | Faraz Ali | Chief Executive Officer | Sell | −9,741 | −$5.24K |
| 2025-03-10 | Whittemore Tingley | Chief Medical Officer | Sell | −7,398 | −$3.98K |
| 2025-03-07 | David V Goeddel | Director | Buy | +35,714,284 | +$25.00M |
| 2025-03-07 | COLUMN GROUP III GP, LP | 10%+ Owner | Buy | +214,285,704 | +$150.00M |
| 2025-02-07 | Faraz Ali | Chief Executive Officer | A | +141,924 | — |
| 2025-01-28 | Whittemore Tingley | Chief Medical Officer | A | +71,676 | — |
| 2024-11-18 | Chihiro Saito | SVP, Accounting and Fin. Ops. | Sell | −2,258 | −$4.79K |
| 2024-10-21 | David V Goeddel | Director | A | +34,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David V Goeddel | Director | 4,985,570 | $2.04M |
| TCG Opportunity III GP, LLC | 10%+ Owner | 4,253,298 | $1.74M |
| Column Group Opportunity III GP, LP | 10%+ Owner | 2,374,048 | $970.04K |
| Deepak Srivastava | Director | 564,101 | $230.49K |
| Faraz Ali | Chief Executive Officer | 539,782 | $220.55K |
| Whittemore Tingley | Chief Medical Officer | 263,073 | $107.49K |
| Tomohiro Higa | SVP, Finance | 118,267 | $48.32K |
| Chihiro Saito | SVP, Accounting and Fin. Ops. | 60,983 | $24.92K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TNYA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.